Overview Dividends

(SEM) Select Medical Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US81619Q1058

Hospitals, Rehab, Outpatient, Therapy

SEM EPS (Earnings per Share)

EPS Growth (3Y CAGR): 1.63%
EPS Trend (3Y Correlation): -15.2%

SEM Revenue

Revenue Growth (3Y CAGR): -5.25%
Revenue Trend (3Y Correlation): -64.5%

Description: SEM Select Medical Holdings August 13, 2025

Select Medical Holdings (NYSE:SEM) is a healthcare company operating in the Health Care Facilities sub-industry. The companys stock performance is influenced by its financial health, operational efficiency, and industry trends.

To evaluate SEMs financial health, key performance indicators (KPIs) such as revenue growth, operating margin, and return on equity (RoE) are crucial. With a RoE of 7.84%, the company generates a relatively modest return for its shareholders. Analyzing the income tax expense on a yearly basis can provide insights into the companys tax strategy and its impact on profitability.

The healthcare facilities sector is driven by demographic trends, such as an aging population, and government policies, including reimbursement rates for healthcare services. Key economic drivers for SEM include the demand for rehabilitation and long-term care services, as well as the overall healthcare spending in the US. The companys market capitalization of $1.46 billion and a forward P/E ratio of 11.45 suggest that investors have certain expectations regarding its future earnings growth.

To further assess SEMs stock, its essential to examine its price movement and trading activity. The stocks beta of 1.048 indicates that it is slightly more volatile than the overall market. Understanding the factors influencing its stock price, such as changes in healthcare policy or shifts in demand for its services, can help investors make informed decisions.

SEM Stock Overview

Market Cap in USD	1,761m
Sub-Industry	Health Care Facilities
IPO / Inception	2009-09-25

SEM Stock Ratings

Growth Rating	-24.6%
Fundamental	36.5%
Dividend Rating	26.0%
Return 12m vs S&P 500	-42.4%
Analyst Rating	4.50 of 5

SEM Dividends

Dividend Yield 12m	1.92%
Yield on Cost 5y	2.20%
Annual Growth 5y	10.02%
Payout Consistency	45.6%
Payout Ratio	17.3%

SEM Growth Ratios

Growth Correlation 3m	66.5%
Growth Correlation 12m	-93.9%
Growth Correlation 5y	13%
CAGR 5y	5.99%
CAGR/Max DD 3y (Calmar Ratio)	0.13
CAGR/Mean DD 3y (Pain Ratio)	0.39
Sharpe Ratio 12m	0.26
Alpha	-42.79
Beta	1.075
Volatility	37.28%
Current Volume	1211.7k
Average Volume 20d	963.9k
Stop Loss	12.8 (-4.3%)
Signal	-0.65

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (110.0m TTM) > 0 and > 6% of Revenue (6% = 322.1m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -1.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1.51% (prev 2.27%; Δ -0.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 407.6m > Net Income 110.0m (YES >=105%, WARN >=100%)

Net Debt (971.5m) to EBITDA (157.4m) ratio: 6.17 <= 3.0 (WARN <= 3.5)

Current Ratio 1.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (NaN) change vs 12m ago NaN% (target <= -2.0% for YES)

Gross Margin 11.57% (prev 12.15%; Δ -0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 78.44% (prev 87.08%; Δ -8.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.06 (EBITDA TTM 157.4m / Interest Expense TTM 117.6m) >= 6 (WARN >= 3)

Altman Z'' 0.81

(A) 0.01 = (Total Current Assets 1.02b - Total Current Liabilities 939.6m) / Total Assets 5.69b

(B) 0.15 = Retained Earnings (Balance) 824.8m / Total Assets 5.69b

(D) 0.22 = Book Value of Equity 818.7m / Total Liabilities 3.67b

Total Rating: 0.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.54

1. Piotroski 1.50pt = -3.50

2. FCF Yield 6.37% = 3.18

3. FCF Margin 3.24% = 0.81

4. Debt/Equity 0.61 = 2.32

5. Debt/Ebitda 6.17 = -2.50

6. ROIC - WACC (= -6.97)% = -8.72

7. RoE 6.51% = 0.54

8. Rev. Trend -64.53% = -4.84

9. EPS Trend -15.18% = -0.76

What is the price of SEM shares?

As of November 06, 2025, the stock is trading at USD 13.37 with a total of 1,211,669 shares traded.
Over the past week, the price has changed by -5.98%, over one month by +2.77%, over three months by +12.27% and over the past year by -30.94%.

Is Select Medical Holdings a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Select Medical Holdings (NYSE:SEM) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 36.54 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SEM is around 11.77 USD . This means that SEM is currently overvalued and has a potential downside of -11.97%.

Is SEM a buy, sell or hold?

Select Medical Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SEM.

Strong Buy: 4
Buy: 1
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SEM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	18.3	37.1%
Analysts Target Price	18.3	37.1%
ValueRay Target Price	13	-3.1%

SEM Fundamental Data Overview November 02, 2025

Market Cap USD = 1.76b (1.76b USD * 1.0 USD.USD)
P/E Trailing = 17.961
P/E Forward = 11.2108
P/S = 0.3337
P/B = 0.9632
P/EG = 1.37
Beta = 1.075
Revenue TTM = 5.37b USD
EBIT TTM = 7.54m USD
EBITDA TTM = 157.4m USD
Long Term Debt = 1.69b USD (from longTermDebt, last fiscal year)
Short Term Debt = 213.0m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 971.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.73b USD (1.76b + Debt 1.03b - CCE 60.1m)
Interest Coverage Ratio = 0.06 (Ebit TTM 7.54m / Interest Expense TTM 117.6m)
FCF Yield = 6.37% (FCF TTM 174.0m / Enterprise Value 2.73b)
FCF Margin = 3.24% (FCF TTM 174.0m / Revenue TTM 5.37b)
Net Margin = 2.05% (Net Income TTM 110.0m / Revenue TTM 5.37b)
Gross Margin = 11.57% ((Revenue TTM 5.37b - Cost of Revenue TTM 4.75b) / Revenue TTM)
Gross Margin QoQ = 10.81% (prev 11.60%)
Tobins Q-Ratio = 0.48 (Enterprise Value 2.73b / Total Assets 5.69b)
Interest Expense / Debt = 2.91% (Interest Expense 30.0m / Debt 1.03b)
Taxrate = 21.01% (11.7m / 55.9m)
NOPAT = 5.95m (EBIT 7.54m * (1 - 21.01%))
Current Ratio = 1.09 (Total Current Assets 1.02b / Total Current Liabilities 939.6m)
Debt / Equity = 0.61 (Debt 1.03b / totalStockholderEquity, last quarter 1.69b)
Debt / EBITDA = 6.17 (Net Debt 971.5m / EBITDA 157.4m)
Debt / FCF = 5.58 (Net Debt 971.5m / FCF TTM 174.0m)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.93% (Net Income 110.0m / Total Assets 5.69b)
RoE = 6.51% (Net Income TTM 110.0m / Total Stockholder Equity 1.69b)
RoCE = 0.22% (EBIT 7.54m / Capital Employed (Equity 1.69b + L.T.Debt 1.69b))
RoIC = 0.17% (NOPAT 5.95m / Invested Capital 3.50b)
WACC = 7.14% (E(1.76b)/V(2.79b) * Re(9.98%) + D(1.03b)/V(2.79b) * Rd(2.91%) * (1-Tc(0.21)))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 75.41% ; FCFE base≈245.4m ; Y1≈302.8m ; Y5≈516.6m
Fair Price DCF = 50.74 (DCF Value 6.28b / Shares Outstanding 123.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -15.18 | EPS CAGR: 1.63% | SUE: 0.54 | # QB: 0
Revenue Correlation: -64.53 | Revenue CAGR: -5.25% | SUE: 0.06 | # QB: 0

Additional Sources for SEM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle